David Cibula

机构：Charles University, General University Hospital in Prague · ORCID：0000-0001-6387-9356

发表论文 923 篇 · 总被引 27184 次 · h-index 78

代表论文

• Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial (2026 · Gynecologic Oncology · 被引 2)
• Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study (2026 · Gynecologic Oncology · 被引 2)
• Lymphatic dissemination in gynecologic malignancies: major anatomical pathways (2026 · International Journal of Gynecological Cancer · 被引 2)
• Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research (2026 · The Lancet Oncology · 被引 1)
• Adjuvant Chemotherapy and Survival After Pelvic Exenteration for Gynecologic Cancers in the COREPEX Study (2026 · JAMA Network Open · 被引 1)
• Puxitatug samrotecan (AZD8205) vs chemotherapy in patients with B7-H4–selected advanced/metastatic endometrial cancer: The phase 3 randomized Bluestar-Endometrial01 (BE01)/GOG-3110/ENGOT-EN28 trial. (2026 · Journal of Clinical Oncology · 被引 1)